骨桥蛋白与颅咽管瘤预后的相关性研究
|
摘要
目的:本研究探讨OPN mRNA在颅咽管瘤的表达情况,OPN及其主要受体整合素αvβ3的蛋白表达,并讨论其与颅咽管瘤复发及复发后生长速度的关系,为预测颅咽管瘤的侵袭性生长及复发提供有效依据。
方法:自2005年11月至2007年7月共收集65例颅咽管瘤患者的手术标本及临床资料,其中釉质上皮型32例,鳞状乳头型33例。随访至2008年3月,进行前瞻性队列研究。FQ-PCR(Fluorescence quantitative polymerase chain reaction,荧光定量PCR)技术检测颅咽管瘤OPN mRNA,免疫组织化学S-P法检测OPN及整合素αvβ3的表达,观察OPN mRNA及其蛋白的表达与颅咽管瘤预后的关系;利用Cavalieri原理计算36例术后复发的颅咽管瘤体积,计算生长速度,探讨OPN mRNA的表达与复发颅咽管瘤生长速度的关系;观察OPN的受体整合素αvβ3的表达与颅咽管瘤预后的关系。
结果:32例釉质上皮型组11例患者复发,33例鳞状乳头型组3例患者复发。釉质上皮型组与鳞状乳头型组间复发率和OPN mRNA及其蛋白的表达差异均有统计学意义(P＜0.05);36例术后复发颅咽管瘤的生长速度在釉质上皮型和鳞状乳头型两者之间有显著性差异(P＜0.05),OPN mRNA Ct值与其生长速度明显负相关(P＜0.05)。整合素αvβ3的表达在釉质上皮型颅咽管瘤和鳞状乳头型之间有显著差异(P＜0.05)。颅咽管瘤中OPN与整合素αvβ3的表达明显正相关(P＜0.05)。
结论:OPN在颅咽管瘤中表达。OPN mRNA表达与颅咽管瘤的复发及复发生长速度正相关。整合素αvβ3表达强度与颅咽管瘤的预后及复发有关。OPN通过整合素αvβ3促进颅咽管瘤复发及侵袭性生长,可能预测颅咽管瘤复发的危险。
[Objective]:In the present study,we investigated the changes in the expression of OPN mRNA and its main receptor integrin alpha v beta 3(αvβ3)in craniopharyngioma,and further discussed the relationship between this factor and craniopharyngioma recurrence as well as the growth velocity after relapse,aiming to provide an effect way to predict the recurrence of craniopharyngioma and the condition of infiltrative growth.
[Methods]:We all collected 65 operation examples and clinical data from the craniopharyngioma patients since Nov.2005 to Jul 2007 Of the 65 examples,there are 32 Adamantine Epithelioma(AE)examples and 33 Squamous Papillary Tumor (SP).Follow-up visit to Mar 2008,we begin to prospective cohort study.To detect OPN mRNA of craniopharyngioma and the expression of OPN and integrinαvβ3,we use the techniques of fluorescence quantitative polymerase chain reaction(FQ-PCR) and immunohistochemical S-P method.Moreover,Cavalieri principle was adopted to calculate the volume and growth velocity of the 36 recurrence examples following operation in this study.
[Results]:Of the 32 AE examples and 33 SP examlpes,there were 11 and 3 examples relapsed respectively.They all had statistical significance(P＜0.05)of relapse rate between AE and SP groups and OPN mRNA as well as its diffrential expression of protein.Furthermore,there was an significant difference(P＜0.05)of growth velocity between AE and SP types in the 36 recurrence examples following operation,but there was an apparent negative correlation(P＜0.05)shown in the Ct values. Comparetively,there was a significant difference in the expression of integrinαvβ3 between AE and SP groups,and there was shown an obviously positive correlation in the expression between OPN and integrinαvβ3 in craniopharyngioma.
[Conclusion]:1.There is an expression of OPN in craniopharyngioma;2.The relationship between the expression of OPN mRNA and craniopharyngioma relapse as well as the growth velocity after relapse is showed an positive correlation;3.Integrinαvβ3 exression may play an important role in craniopharyngioma and its prognosis as well as recurrence.4.OPN promoting the craniopharyngioma relapses and invasive growth by integrinαvβ3,might be predict the risk of craniopharyngioma relapse.
方法:自2005年11月至2007年7月共收集65例颅咽管瘤患者的手术标本及临床资料,其中釉质上皮型32例,鳞状乳头型33例。随访至2008年3月,进行前瞻性队列研究。FQ-PCR(Fluorescence quantitative polymerase chain reaction,荧光定量PCR)技术检测颅咽管瘤OPN mRNA,免疫组织化学S-P法检测OPN及整合素αvβ3的表达,观察OPN mRNA及其蛋白的表达与颅咽管瘤预后的关系;利用Cavalieri原理计算36例术后复发的颅咽管瘤体积,计算生长速度,探讨OPN mRNA的表达与复发颅咽管瘤生长速度的关系;观察OPN的受体整合素αvβ3的表达与颅咽管瘤预后的关系。
结果:32例釉质上皮型组11例患者复发,33例鳞状乳头型组3例患者复发。釉质上皮型组与鳞状乳头型组间复发率和OPN mRNA及其蛋白的表达差异均有统计学意义(P＜0.05);36例术后复发颅咽管瘤的生长速度在釉质上皮型和鳞状乳头型两者之间有显著性差异(P＜0.05),OPN mRNA Ct值与其生长速度明显负相关(P＜0.05)。整合素αvβ3的表达在釉质上皮型颅咽管瘤和鳞状乳头型之间有显著差异(P＜0.05)。颅咽管瘤中OPN与整合素αvβ3的表达明显正相关(P＜0.05)。
结论:OPN在颅咽管瘤中表达。OPN mRNA表达与颅咽管瘤的复发及复发生长速度正相关。整合素αvβ3表达强度与颅咽管瘤的预后及复发有关。OPN通过整合素αvβ3促进颅咽管瘤复发及侵袭性生长,可能预测颅咽管瘤复发的危险。
[Objective]:In the present study,we investigated the changes in the expression of OPN mRNA and its main receptor integrin alpha v beta 3(αvβ3)in craniopharyngioma,and further discussed the relationship between this factor and craniopharyngioma recurrence as well as the growth velocity after relapse,aiming to provide an effect way to predict the recurrence of craniopharyngioma and the condition of infiltrative growth.
[Methods]:We all collected 65 operation examples and clinical data from the craniopharyngioma patients since Nov.2005 to Jul 2007 Of the 65 examples,there are 32 Adamantine Epithelioma(AE)examples and 33 Squamous Papillary Tumor (SP).Follow-up visit to Mar 2008,we begin to prospective cohort study.To detect OPN mRNA of craniopharyngioma and the expression of OPN and integrinαvβ3,we use the techniques of fluorescence quantitative polymerase chain reaction(FQ-PCR) and immunohistochemical S-P method.Moreover,Cavalieri principle was adopted to calculate the volume and growth velocity of the 36 recurrence examples following operation in this study.
[Results]:Of the 32 AE examples and 33 SP examlpes,there were 11 and 3 examples relapsed respectively.They all had statistical significance(P＜0.05)of relapse rate between AE and SP groups and OPN mRNA as well as its diffrential expression of protein.Furthermore,there was an significant difference(P＜0.05)of growth velocity between AE and SP types in the 36 recurrence examples following operation,but there was an apparent negative correlation(P＜0.05)shown in the Ct values. Comparetively,there was a significant difference in the expression of integrinαvβ3 between AE and SP groups,and there was shown an obviously positive correlation in the expression between OPN and integrinαvβ3 in craniopharyngioma.
[Conclusion]:1.There is an expression of OPN in craniopharyngioma;2.The relationship between the expression of OPN mRNA and craniopharyngioma relapse as well as the growth velocity after relapse is showed an positive correlation;3.Integrinαvβ3 exression may play an important role in craniopharyngioma and its prognosis as well as recurrence.4.OPN promoting the craniopharyngioma relapses and invasive growth by integrinαvβ3,might be predict the risk of craniopharyngioma relapse.
引文
1.Schut L.Management of a pediatric hypothalamic mass.Neurosurgery.1996,38(4):806-811.
2.Till K.Craniopharyngiomas.Childs Brain,1982,9:179.
3.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
4.Yasargil MG craniopharyngiomas.IN:Microneurosurgery of CNS Tumors,ed.Yasargil MG,Thieme,Medical Publishers,Inc,New York,1996,214.
5.Coutant R,Maurey H,Rouleau S,et al.Defect in epinephrine production in children with craniopharyngioma:functional or organic origin? J Clin Endocrinol Metab,2003,88(12):5969-5975.
6.Rojas EL,Al-Dweri FM,Lallena AM,et al.Dosimetry for radiocolloid therapy of cystic craniopharyngiomas.Med Phys,2003,30(9):2482-2492.
7.Caldarelli M,Di Rocco E,Papaci F,et al.Management of recurrent craniopharyngioma.Acta Neurochir(Wien),1998,140(5):447-454.
8.Wang KC,Kim SK,Choe G,et al.Growth patterns of craniopharyngioma in children:role of the diaphragm sellae and its surgical implication.Surg Neurol,2002,57(1):25-33.
9.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21(6):747-757.
10.漆松涛,潘军,黄胜平等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神经精神疾病杂志,2002,28(4):268-272.
11.漆松涛,潘军,陈状.儿童巨大颅咽管瘤12例手术治疗.中国神经精神疾病杂志,2004,30(6):475-476.
12.Im SH,Wang KC,Kim SK,et al.Transsphenoidal microsurgery for pediatric craniopharyngioma:special considerations regarding indications and method.Pediatr Neurosurg,2003,39(2):97-103.
13.Reyes F.Craniopharyngioma Recurrence.An R Acad Nac Med(Madr),2001,118(2):263-273.
14.Adamson TE,Wiestler OD,Kleihues P,et al.Correlation of clinical and pathological features in surgically treated craniopharyngiomas.J Neurosurg,1990,73:12-17.
15.Weiner HL,Wisoff JH,Rosenberg ME,et al.Craniopharyngiomas:A clinicopathological analysis of factors predictive of recurrence and functional outcome.Neurosurgery,1994,35(6):1001-1011.
16.Crotty TB,Scheithauer BW,Young WF,et al.Papillary craniopharyngioma:a clinicopathological study of 48 cases.J Neurosurg,1995,83(2):206-214.
17.Fahlbusch R,Honegger J,Paulus W,et al.Surgical treatment of craniopharyngiomas:experience with 168 patients.J Nurosurg,1999,90:237-250.
18.Eldevik OP,Blaivas M,Gabrielsen TO,et al.Craniopharyngioma:radiologic and histologic findings and recurrence.AJNR Am J Neuroradiol,1996,17(8):1427-1439.
19.Sweet WH.Craniopharyngiomas:asummaryofdata.In:Schmidek HH,ed.Operative neurosurgical techniques.4thed.London:ElsevierScience,2002:477-486.
20.潘军,漆松涛,邓永健,等.颅咽管瘤增殖细胞核抗原表达与肿瘤复发的关系.第一军医大学学报,2002,22(4):363-365.
21.Nishi T,Kurastu J,Takeshima H,et al.Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma.Int J Mol Med,1999,3(2):157-161.
22.Raghavan R,William T,Dickey,J,et al.Proliferative activity in craniopharyngiomas:clinicopathological correlations in adults and children.Surg Neurol,2000,54(3):241-248.
23.Beck GR Jr, Zerler B, Moran E.Phosphate is a specific signal for inductionof osteopontin gene expression. Proc Natl Acad Sci U S A, 2000, 97(15): 8352 - 8357.
24.Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J, 1993, 7(15):1475 -1482.
25.Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998, 30: 92 - 102.
26.Agrawal D, chen T, Irby R, etal. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst, 2003, 326 (10 - 11): 1041-1043.
27.Giancotti FG, Ruoslahti E. Integrin signaling. Science, 1999,285(5430): 1028 - 1032.
1.Agrawal D,chen T,Irby R,etal.Osteopontin identified as lead marker of colon cancer progression,using pooled sample expression profiling.J Natl Cancer Inst,2003;326(10-11):1041-1043.
2.Ishida K,Zhu BL,Maeda H.Novel approach to quantitative reverse transcription PCR assay of Mma component in autopsy material using the TaqMan fluorogenic detection system:dynamics of pulmonary surfactant apoprotein A.Forensic Sci Int.2000,113(1-3):127-131.
3.Higuchi R,Fockler C,et al.Kinetic PCR analysis:real-time monitoring of DNA amplification reactions.Biotechnology.1993,11(9):1026-1030.
4.Willard MR,Stephen JW,Kent EV Quantitative PT-PCR:pitfalls and potential.Biotechniques.1999,26,112-125.
5.Gabriel L,Armando P,Aidier S,et al.Craniopharyngioma in children:Marseille experience.Childs New Syst,2005,21(5):778-784.
6.Im SH,Wang KC,Kim SK,et al.Transsphenoidal microsurgery for pediatric craniopharyngioma:special considerations regarding indications and method.Pediatr Neurosurg,2003,39(2):97-103.
7.Kahn EA,Gosch HH,Seeger JF,et al.Forty-five years experience with the craniopharyngiomas.Surg Neurol,1973;1(3):5-12.
8.Weiner HL,Wisoff JH,Rosenberg ME,et al.Craniopharyngiomas:A clinicopathological analysis of factors predictive of recurrence and functional outcome.Neurosurgery,1994,35(6):1001-1011.
9.Adamson TE,Wiestler OD,Kleihues P,et al.Correlation of clinical and pathological features in surgically treated craniopharyngiomas.J Neurosurg,1990,73(1):12-17.
10.Fahlbusch R,Honegger J,Paulus W,et al.Surgical treatment of craniopharyngioma:experience with 168 patients.J Neurosurg,1999,90(2):237-250.
11.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21:747-757.
12.李士其.颅咽管瘤.见:徐启武,蒋雨平主编.第1版.临床颅脑病学.天津:天津科学技 术出版社,2003:278-283.
13.Kim SK,Wang KC,Shin SH,et al.Radical excision of pedi-atric craniopharyngioma:recurrence pattern and prognosticfac-tors.Child's Nerv Syst,2001,17(9):531-537.
14.Reizo Shirane,Ching-chanSu,YasukoKusaka,et al.Surgical outcomes in 31 patients with craniopharygiomas extending out-side the suprasellarcistern:ane valuation of the front obasalin-terhemispheric approach.J Neurosurg,2002,96(1):704-708.
15.潘军,漆松涛,邓永键等.颅咽管瘤增殖细胞核抗原表达与肿瘤复发的关系.第一军医大学学报,2002,22(4):363-366.
16.Sweet WH.Craniopharyngiomas:asummaryofdata.In:Schmidek HH,ed.Operative neurosurgical techniques.4thed.London:Elsevier Science,2002:477-486.
17.Senger DR,Wirth DF,Hynes R0.Transformed mammalian cells secrete specific proteins and phosphoproteins.Cell.1979,16(4):885-893.
18.Senger DR,Wirth DF,Hynes R0.Transformation-specific secreted phosphoproteins.Nature.1980,286(5773):619-621.
19.Oldberg A,Franzen A,Heinegard D.Cloning and sequence analysis of rat bone sialoprotein(osteopontin)cDNA reveals an Arg-Gly-Asp cell binding sequence.proc Natl Acad Sci USA.1986,83(23):8819-8823.
20.Coppola D,Correlation of osteopontin protein expression and pathological stage across a wide variety oftumorhistologies.Clin Cancer Res.2004,10(1):184-190.
21.Tuck AB,Chambers AF.The role of osteopontin in breast cancer:clinical and experimental studies.J Mammary Gland Biol Neoplasia,2001;6(4):419-429.
22.Ue T,Yokozaki H,Kitadai Y,et al.Co-expression of osteopontin and CD44v9 in gastriccancer.Int J Cancer.1998,79(2):127-132.
23.Casson AG,Wilson SM,McCart JA,etal.Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer.Int J Cancer,1997,72(5):739-745.
24.Thalmann GN,Sike RA,Devoll RE,et al.Osteopontin:possible role in prostate cancer progress.Clinical Cancer Res,1999,5(8):2271-2277.
25.Otte SJ,Winquist EW,Sititt L,et al.Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.Cancer.2002,95(3): 506-512.
26 Furger KA,Menon RK,Tuckl AB,et al.The functional and clinical roles of osteopontin in cancer and metastasis.Curr M1 Med.2001,1(5):621-632.
27.Tuck AB,O'Mallet FP,Singhal H,et al.Osteopontin and p53 expression are associated with tumor progression in a case of synchronous,bilateral,invasive mammary carcinomas.Arch Pathol Lab Med.1997,121(6):578-584.
28.Ye QH,Qin LX,Forgues M,et al.Predicting bepatitis B vinus-positive metastatic hepatocellular carcinomas using gene expression prof-fling and supervised machine learning.Nature Med.2003,9(4):416-423.
29.Shi jubo N,Uded T,Koo S,et al.Vascular endothelial growth facto and osteopontin in tumor biology.Crit Rev Oncog.2000,11(2):135-146.
30.Tuck AB,Chambers AF.The role of osteopontin in breast cancer:clinical and experimental studies.J Mamnar Y Gland Biol Neoplasia.2001,6(4):419-429.
31.Weinberger KM,Wiedenmann E,Bohm S,et al.Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system(Taq Man PCR).J Virol Methods.2000,85(1-2):75-82.
32.Eun AJ,Soeh M,Wong S,et al.Simultaneous quantitation of two orchid viruses by the Taq Man real-time RT-PCR.J Virol Methods.2000,87(1-2):151-160.
33.蒋春燕,王泰健,王琴.实时荧光定量PCR技术.动物医学进展.2005,12(1):101-105.
34.Kong DM,Huang YP,Zhang XB,et al.Duplex probes:a new approach for the detection of specific nucleic acids in homogenous assays.Analytic Chimica Acta,2003,491(3):135-143
35.张望.荧光实时定量PCR技术初探.生命科学趋势,2003,1(4):13-41.
36.Klein D.Quantification using real-time PCR technology:Applications and limitations.Trends Mol Med,2004,8(6):257-266
37.Sanford RA,Muhlbauer MS.Craniopharyngioma in children.Neurologic clinics,1991,9:453-465.
38.Lefranc F,Chevalier C,Vinchon M,et al.Characterization of the levels of expression of retinoic acid receptors,galectin-3,macrophage migration inhibiting factor,and p53 in 51adamantinomatous craniopharyngiomas.J eurosurg,2003,98(1):145-153.
39.漆松涛,潘军,黄胜平,等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神 经精神疾病杂志,2002,28(4):268-272.
40.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
1.Anderson RC,Grant JJ,de la Paz R,et al.Volumetric measurements in the detection of reduced ventricular volume in patients with normal pressure hydrocephalus whose clinical condition improved after ventriculoperitoneal shunt placement.J Neurosurg.2002,97(1),73-79.
2.Clatterbuck RE,Sipos EP.The efficient calculation of neurosurgically relevant volumes from computed tomographic scans using Cavalieri's Direct Estimator.Neurosurgery.1997,40(2):339-343.
3.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
4.Yasargil MG craniopharyngiomas.IN:Microneurosurgery of CNS Tumors,ed.Yasargil MG,Thieme,Medical Publishers,Inc,New York,1996,214.
5.Coutant R,Maurey H,Rouleau S,et al.Defect in epinephrine production in children with craniopharyngioma:functional or organic origin? J Clin Endocrinol Metab,2003,88(12):5969-5975.
6.Rojas EL,Al-Dweri FM,Lallena AM,et al.Dosimetry for radiocolloid therapy of cystic craniopharyngiomas.Med Phys,2003,30(9):2482-2492.
7.Caldarelli M,Di Rocco E,Papaci F,et al.Management of recurrent craniopharyngioma.Acta Neurochir(Wien),1998,140(5):447-454.
8.Wang KC,Kim SK,Choe G,et al.Growth patterns of craniopharyngioma in children:role of the diaphragm sellae and its surgical implication.Surg Neurol,2002,57(1):25-33.
9.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21(6):747-757.
10.漆松涛,潘军,黄胜平等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神经精神疾病杂志,2002,28(4):268-272.
11.漆松涛,潘军,陈状.儿童巨大颅咽管瘤12例手术治疗.中国神经精神疾病杂志,2004,30(6):475-476.
12.Ito M,Jamshidi J,Yamanaka K.Dose craniopharyngioma metastasize? case report and review of the literature.Neurosrugery,2001,48(4):933-935.
13.Novegno F,Di Rocco F,Colosimo Jr C,et al.Ectopic recurrences of craniopharyngioma.Childs New Syst,2002,18(9-10):468-473.
14.Kristopaitis T,Thomas C,Petruzzelli GJ,et al.Malignant craniopharyngioma.Arch Pathol Lab Med,2000;124(9):1356-1360.
15.Medico E,Gentile A,Lo Celso C,et al.Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth.Cancer Res.2001,61(15):5861-5868.
16.Shi jubo N,Uede T,Kon S,et al.Vascular endothelial growth factor and osteopontin in tumor biology.Crit Rev Oncog.2000,11(2):135-146.
17.Denhardt DT,Chamber AF.Overcoming obstacles to metastasis defenses against host defences:osteopontin(OPN)as a shield against attack by cytotoxic host cells.J Cellular Biochem.1994,56(1):48-51.
18.Vacca A,Ria R,Presta M,et al.Integrin alpha V beta 3 engagement modulates cell adehension,proliferation,and protease secretion in human lymphoid tumor cells.Exp Hematol.2001,29(8):993-1003.
19.Hotte S,Winquist EW,Stitt L,et al.Plasma osteopontin associations with survival and metastasis to bone in men with hormone refractory prostate carcinoma.Cancer.2002,95(3):516-512.
20.董俊峰,张占堆.51例颅内血肿量的新法计算探讨.河南实用神经疾病杂志.2002,(2):73-75.
21.Fucci MJ,Buchman CA,Brackmann DE,et al.Acoustic tumor growth:implica tions for treatment choices.Am J Otol.1999,20(4):495-499.
22.Tang Xi,HU Guoqing,Qiu Hong,et al.Comparing gross tumor volume of delineation between CT and MR/for nasopharygeal carcinoma.The Chinese-German Journal of Clinical Oncology.2005,4(3):141-145.
23.Hofmann UB,Westphal JR,Wass ET,et al.Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2(MMP-2)coincides with MMP-2 activation:correlation with melanoma progression.J Invest Dermatol.2000,115(4):625-632.
24.Silletti S,Kesster T,Goldberg J,et al.Disruption of matrix metalloproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo.Proc Natl Acta Sci USA.2001,98(1):119-124.
1.Giancotti FG, Ruoslahti E. Integrin signaling. Science, 1999, 285(5430): 1028 - 1032.
2.Gerber DJ, Pereira P, Huang SY, et allymphocytes. Expression of alpha v and beta 3 integrinchains on Proc Natl Acad Sci USA, 1996, 93(25): 14698 - 14703.
3.Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem, 1996, 271(45): 28485 -28491.
4.Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta, 2001,1552(2): 61-85.
5.Lesse BA. Adhesion molecules and implantation. J Reprod Immunol. 2002,55(1-2): 101-112.
6.Liaw L, Almeida M, Hart C E, et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res, 1994, 74(2): 214 - 224.
7. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol, 1996, 5(2): 127 - 135.
8.Furger KA, Allan AL, Wilson SM,et al. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res, 2003, 1(11): 810-819.
9.Senger DR, Ledbetter SR, Claffey KP, et al.Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol, 1996,149(1): 293-305.
10.Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol, 2000,156(5): 1673 - 1683.
11.Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling,and cell survival. J Clin. Invest, 2001,107(9): 1055-1061.
12.Engleman VW, Nickols GA, Ross FP,et al. A peptidomimetic antagonist of the alpha v beta 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest, 1997, 99(9): 2284-2292.
13.Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 2000,287(5454): 860 - 864.
14. Rabinowich H, Lin WC, Amoscato A,et al.Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. J Immunol,1995,154(3):1124-1135.
15.Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001,1552 (2): 61 - 85.
16.Hofmann UB, Westphal JR, Wass ET, et al. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2(MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol. 2000,115 (4): 625 - 632.
l7.Silletti S, Kesster T, Goldberg J, et al. Disruption of matrix metalloproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo. Proc Natl Acta Sci USA. 2001,98(1): 119- 124.
18.Furger KA, Alian AL, Wilson SM, et al. β_3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res. 2003, 1(11): 810-819.
19.Liapis H, Flath A, Kitazawa S, etal. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996,5 (2): 127 - 135.
20.Hofmann UB, Westphal JR, Wass ET, et al. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol. 2000,115 (4): 625 - 632.
21.Silletti S, Kesster T, Goldberg J, et al. Disruption of matrix metall oproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo. Proc Natl Acta Sci USA.2001, 98(1): 119 - 124.
22.Liu W, Matsumoto Y, Okada M, et al. Matrix metaploproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Medical Investigation. 2005, 52 (3-4): 151-158.
23.Paez PM, Ledda MF, Goldberg V, et al. High level of matrix metal oproteinases regulate proliferation and hormone secretion in pituitary cells. J Clinical Endocrinology Metasbolism. 2000, 85(1):263- 269.
24.Khabit AM, Nip J, Fallavollita L, et al. Regulation of urokinase plasminogen activator/plasmin- mediated invasion of melanoma cells by the integrin vitronectin receptor alpha V bete 3. Int Cance. 2001, 91(3): 300 - 308.
25.Mousa SA, Mohamed S, Wexler EJ, et al. Antiangiogenesis anticancer efficacy of TA138, a novel alpha V beta 3 antagonist. Anticancer Research. 2005,5 (1A): 197 - 206.
1.Beck GR Jr,Zerler B,Moran E.Phosphate is a specific signal for inductionof osteopontin gene expression.Proc Natl Acad Sci U S A,2000,97(15):8352-8357.
2.Ashkar S,Weber G.F,Panoutsakopoulou V,et al.Eta-1(osteopontin):an early component of type-1(cell-mediated)immunity.Science,2000,287(5454):860-864.
3.Fisher LW,McBride OW,Termine JD,Young MF.Human bone sialoprotein:Deduced protein sequence and chromosomal localization.J Biol Chem,1990,265(4):2347-2351.
4.Kohri K,Nomura S,Kitamura Y,et al.Structure and expression of the mRNA encoding urinary stone protein(osteopontin).J Biol Chem,1993,268(20):15180-15184.
5.Kohri K,Suzuki Y.,Yoshida K,et al.Molecular cloning and sequencing of cDNA encoding urinary stone protein,which is identical to osteopontin.Biochem Biophys Res Commun,1992,184(2):859-864.
6.Denhardt DT,Guo X.Osteopontin:a protein with diverse functions.FASEB J,1993,7(15):1475-1482.
7.Denhardt DT,Noda M.Osteopontin expression and function:role in bone remodeling.J Cell Biochem Suppl.1998,30:92-102.
8.Liaw L,Skinner MP,Raines EW,et al.The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins.Role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995,95(2): 713 - 724.
9. Xuan JW, Hota C, Shigeyama Y, et al. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem, 1995,57:680-690.
10.Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/ osteopontin gene. Crit Rev Immunol, 1993,13:225-246.
11.Scatena M, Almeida M, Chaisson ML, et al. NF-kappaB mediates avp3 integrin-induced endothelial cell survival. J Cell Biol, 1998,141(4): 1083 - 1093.
12.Hwang SM, Lopez CA, Heck DE, et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem. 1994, 269(1): 711-715.
13.Young MF, Kerr JM, Termine JD, et al. cDNA cloning. mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin(OPN). Genomics, 1990, 7: 49- 50.
14.Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.Anticancer Res. 1989, 9: 1291-1299.
15.Humphries MJ, Olden K, Yamada KM. A synthetic peptide from bronectininhibits experimental metastasis of murine melanoma cells. Science. 1986,233:467 - 470.
16.Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E. Role of the αvβ3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A. 1992, 89: 1557-1561.
17.Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and broblastic cells. Nature. 1983, 302: 714 -715.
18.Craig AM, Bowden GT, Chambers AF, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine broblasts. Int J Cancer. 1990,46: 133 - 137.
19.Ye QH, Qin LX, Forgoes M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 2003, 9(4): 416-423.
20.Behrend EI, Craig AM, Wioson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin 57 RNA. Cancer Res. 1994, 54:832 - 837.
21.Gardner HAR, Berse B, Senger DR. Speci.c reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat 1 .broblasts. Oncogene. 1994, 9: 2321 -2326.
22.Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression anddistribution in human carcinomas. Am J Pathol. 1994,145: 610 - 623.
23.Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim 3H, Cramer DW, Berkowitz RS,Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res, 2004,10(10): 3474 - 3478.
24.Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF,Yeatman TJ Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004,10(1 Pt I):184 - 190.
25.Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B,Cheifetz S. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis, 2000,18(3): 253 - 260.
26.Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe 从 Takahashi K, Fukuchi Y, Saijo N,Nishio K. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer, 2002,98(5) 707 -712.
27.Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES,Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem, 2002, 85(4): 728 - 736.
28.Crosby AH, Edwards SJ, Murray JC, Dixon MJ. Genomic organization of the human osteopontin gene: exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfecta type II. Genomics, 1995,27(1): 155 - 160.
29.Kiefer MC, Bauer DM, Barr PJ. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res, 1989,17(8): 3306 - 3312.
30.Shiraga H, Min W, VanDusen WJ, dayman MD, Miner D, Terrell CH, Sherbotie JR,Foreman JW, Prrysiecki C, Neilson EG,. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.Proc Natl Acad Sci U S A, 1992, 89(1): 426-430.
31.Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T lymphocyte activation-1/osteopontin gene. Crit Rev Immunol, 1993,13(3-4): 225 - 246.
32.Yamamoto S, Hijiya N, Setoguchi M, et al. Structure of the osteopontin gene and its promoter. Ann N Y Acad Sci, 1995, 760: 44 - 58.
33.O'Regan A,Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol, 2000,81(6): 373 - 390.
34.Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J, 1985,232(3): 715 - 724.
35.Oldberg A, Franzen A,Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A, 1986, 83(23): 8819 -8823.
36.Saitoh Y,Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest, 1995,72(1): 55 - 63.
37.Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta, 2001,1552(2): 61 - 85.
38.Bautista DS, Denstedt J, Chambers AF,Harris JF. Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem, 1996, 61(3): 402 - 409.
39.Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin - cleavage fragment of osteopontin. Biochim Biophys Acta, 1996,1314(1-2): 13-24.
40.Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res, 1985,45: 5818 - 5823.
41.Senger DR, Perruzzi CA, Papadopoulos-Sergiou A,Van de WL. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell, 1994, 5(5): 565 - 574.
42.Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ,Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 2000, 287(5454): 860 - 864.
43.Helluin O, Chan C, Vilaire q Mousa S, DeGrado WF,Bennett JS. The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem, 2000,275(24): 18337 - 18343.
44.Denhardt DT, Noda M, O'Regan AW, Pavlin D,Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest, 2001,107(9): 1055 - 1061.
45.Smith LL,Giachelli CM. Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res, 1998,242(1): 351 - 360.
46.Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R,Giachelli CM. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9betal integrin. J Biol Chem, 1996,271(45): 28485 - 28491.
47.Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SWYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem, 1999,274(51): 36328 - 36334.
48.Rangaswami H, Bulbule A, Kundu GC.Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol, 2006,16(2): 79 - 87.
49.Rittling SR, Chambers AF, et al. Role of osteopontin in tumor progression. Br J Cancer, 2004, 90(10): 1877-1881.
50.Wai PY, Kuo PV The role of osteopontin in tumor metastasis.J Surg Res, 2004, 121(2): 228-241.
51.Chakraborty G, Jain S, Behera R, et al. The multifaceted role of osteopontin in cell signaling tumor progression and angiogenesis. Curr Mol Med, 2006, 6(8): 819 - 830.
52. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF,Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol, 1994,145(3): 610-623.
53.Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer, 1996,15(3): 311 - 323.
54.Maki M, Hirota S, Kaneko Y,Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int, 2000,50(7): 531 - 535.
55.Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF,Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004,10(1): 184 - 190.
56.Crawford HC, Matrisian LM,Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res, 1998, 58(22): 5206 -5215
57.Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem, 2000, 77(3): 487 - 498.
58.Bourassa B, Monaghan S,Rittling SR. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol, 2004,227(1): 1-11.
59.Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB,Mukherjee BB. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry, 1997,36(19): 5729 - 5738.
60.Sodek J., Ganss B, Mckee MD. Osteopontin. Crti. Rev Oral Biol Med, 2000,11(3):279-303. 61.Chambers AF, Macdonald IC, Schmidt EE, et al. Clinical targets for anti- metastasis therapy. Adv Cancer Res, 2000, 79:91-121.
62.Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov, 2003,2(9): 703 - 716.
63.Weber GF. The metastasis gene osteopontin: a candidate for cancer therapy. Biochim. Biophy Acta, 2001,1552(2): 61 - 85.
64.Marroquin CE, Downky L, Guo H, et al. Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 marine leukemia cells [J]. Immunol Lett, 2004,95(1): 109 - 112.
65 .Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6,v9) expressicn by osteopontin in breast cancer epithelial cells facilitates tumor cell migratioru: novel post-transcriptional, post-translational regulation. Clin Exp Metastas, 2005,22(8): 663 - 673.
66.Al-Sharni K, Sorensen ES, EK-Rylander B, et al. Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 s6 kinase-dependent pathway. J Cell Biochem, 2005,94(6): 1218 - 1233.
67.Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear ractor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem, 2003, 278(31): 28593-28596.
68.Daffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des, 2004,10(1): 39-49.
69.Miz Guy H, Wai PY, et al. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in marine mammary epithelial cancer cells. Carcinogenesis, 2006,27(6): 1134 - 1145.
70.Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK /I_κB_α kinase-dependent nuclear factor κB-mediated promatrix, metalloproteinase-9 activation. J Biol Chem, 2004, 279(37): 38921 - 38935.
71.Rangasvrami H, Bulbule A, Kundu GC. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem, 2005, 280(19): 19381 - 392.
72.Jain S, Chakraborty q Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alphal/c-Src/IkappaB kinase kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res, 2006, 66(13): 6638 - 6648.
73.Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for abgiogenesis. Science, 1994, 264(5158): 569 - 571.
74. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and rumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival [J]. Mol Biol Cell, 2004, 15(6): 2834 - 2841.
75.Takahashi F, Akutagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer, 2002, 98(5): 707 - 712.
76.Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia, 2001, 6(4): 419 - 429.
77.Carlinfante G,Vassiliou D,Svensson O,et al.Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.Clin Exp Metastasis,2003,20(5):437-444.
78.Fedarko NS,Jain A,Karadag A,et al.Elevated serum bone sialoprotein and osteopontin in colon,breast,prostate,and lung cancer.Clin Cancer Res,2001,7(12):4060-4066.
79.Forootan SS,Foster CS,Aachi VR,et al.Prognostic si加ficance of osteopontin expression in human prostate cancer.Int J Cancer,2006,118(9):2255-2261.
80.Irby RB,McCarthy SM,Yeatman TJ.Osteopontin regulates multiple functions contributing to human colon cancer development and progression.Clin Exp Metastasis,2004,21(6):515-523.
81.Zhou Y,Dai DL,Martinka M,et al.Osteopontin expression correlates with melanoma invasion.J haves Dermatol,2005,124(5):1044-1052.
82.Boldrini L,Donati V,Dell'Omodarme M,et al.Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer.Br J Cancer,2005,93(4):453-457.
83.Kao CL,Chio SH,Ho DM et al.Elevation of plasma and cerebrospinal fluid Pathol,2005,123(2):297-304.
84.Wong TS,Kwong YL,Yuen AP.Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma.Eur J Surg Oncol,2005,31(5):555-558.
85.丁凌,郑树.骨桥蛋白在大肠癌和大肠癌肝转移中的表达及其临床意义.中华外科杂志,2002,40(10):773-775.
86.Renault MA,Jalvy S,Belloc I,Pasquet S,Sena S,Olive M,Desgranges C,Gadeau AP.AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells.Circ Res,2003,93(7):674-681.
87.Kohri K,Nomura S,Kitamura Y,Nagata T,Yoshioka K,Iguchi M,Yamate T,Umekawa T,Suzuki Y,Sinohara H,.Structure and expression of the mRNA encoding urinary stone protein (osteopontin).J Biol Chem,1993,268(20):15180-15184.
88.Yoshitake H,Riffling SR,Denhardt DT,Noda M.Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.Proc Natl Acad Sci U S A,1999,96(14):8156-8160.
89.Singh K,Balligand JL,Fischer TA,Smith TW,Kelly RA.Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells.Role in regulation of inducible nitric oxide synthase. J Biol Chem, 1995, 270(47): 28471 - 28478.
90.Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fieck E,Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation, 1997,96(9): 3063-3071.
91.Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM,Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (sppl). J Clin Invest, 1998,101(7): 1468 - 1478.
1.Schut L.Management of a pediatric hypothalamic mass.Neurosurgery.1996,38(4):806-811.
2.Till K.Craniopharyngiomas.Childs Brain,1982,9:179.
3.Sweet WH.Craniopharyngiomas:a summary of data.In:Schmidek HH,ed.Operative neurosurgical echniques.4~(th)ed.Vol 1,Health Science Asia,Elsevier cience;2002:477-486.
4.周良辅,主编.现代神经外科学.第一版.上海:上海医科大学出版社.2001.547-555.
5.姚志彬,主编.临床神经解剖学.第1版.广州:广东世界图书出版社.2001,255-290.
6.Lipscombe,Lorraine MD,Asa,Sylvia L.et al.Management of Lesions of the Pituitary Stalk and Hypothalamus.Endocrinologist.2003,13(1):38-51.
7.Henry,Thomas R.MD.Therapeutic mechanisms of vagus nerve stimulation.Neurology,2002,59(6):513-514.
8.Goldberg GM,Eshbaugh DE.Squamous cell nests of the pituitary gland as related to the origin of craniopharyngiomas:a study of the presence in the newborn and infants up to age four.Arch pathol,1996(70),293.
9.Shigeki Sekine,Tatsuhiro Shibata,Akiko Kokubu,et al.Craniopharygiomas of Adamantinomatoud Type Harbor β-Catenin Gene Mutations.American Journal of pathology,2002,161:1997-2001.
10.Rienstein S,Adams EF,Pilzer D,et al.Comparative genomic hybridization analysis of craniophryngioma.Journal of Neurosurgery,2003,98(1):162-164.
11.Alex F,Lesley S,Morris A,et al.Clinical Cancer Research.1999,5:2121-2132.
12.Paulus W,Stockel C,Krauss J,et al.Odontogenic classification of craniopharyngiomas:a cliniccopathological study of 54 cases.Histopathology,1997,30(2):172-176.
13.Adamson TE,Wiestler OD,Kleihues P,et al.Correlation of clinical and pathological features in surgically treated cranopharyngiomas.J Neurosurg,1990,73:12-17.
14.Xin W,Rubin MA,Mckeever.Differential expression of cytokerating 8 and 20distinguishes craniopharygioma from rathke cleft cyst.Archives of Pathology & Laboratory Medicine.2002,126(10):1174-1178.
15.Kawamata T, Kubo O, kamikawa S, et al. Ectopic clival craniopharyngioma. Acta Neurochirurgica, 2002,144(11): 1221 - 1224.
16.Liu JM, Garonzik IM, CG, et al. Ectopic recurrence of craniopharygioma after an interhenvspheric transcallosal approacha: case report.Neurosurgery. 2002,50(3): 639 - 644.
17.Henry H, Schmidek, MD, FACS. Operative neurosurgical techniques fourth edition. Health science Asia, Elsevier Science, 2002,477 - 511.
18.Hekmatpanah, Javad, et al. Transcortical-transventricular approach for removal of large third ventricle tumors. J Neurooncol, 2000,46(3): 277 - 280.
19.Belsham, Denise D, Cai, et al. Generation of a phenotypic array of hypothalamic neuronal cell models to study complex neuroendocrine disorders. Endocrinology. 2004,145(1): 393 - 400.
20.Funahashi H, Takenoya F, Guan Jl, et al. Hypothalamic neuronal networks and feeding-related peptides involved in the regulation of feeding. Anatomical Science International.2003 Sep, 78(3): 123 - 138.
21.Jung, H; Probst, E Neumaier, et al. Association of Morphological Characteristics with Precocious Puberty and/or Gelastic Seizures in Hypothalamic Hamartoma. Journal of Clinical Endocrinology & Metabolism. 2003, 88(10): 4590 - 4595.
22.Cho YK, Li CS, Smith DV ,et al. Descending influences from the lateral hypothalamus and amygdala converge onto medullary taste neurons. Chem. Senses 2003,28(2): 155 - 171.
23.Yang YK, Harmon CM, et al. Recent developments in our understanding of melanocortin system in the regulation of food intake. Obes Rev, 2003,4(4): 239 - 248.
24.Jansen HT, Cutter, et al. Seasonal Plasticity within the onadotropin-Releasing (GnRH) System of the Ewe: Changes in Identified GnRH Inputs and Glial Association. [Miscellaneous Article] .Endocrinology. 2003 Aug, 144(8): 3663 - 3676.
25.Henry H. Schmidek, MD, FACS. Operative neurosurgical techniques. Fourth Edition, Health science Asia, Elsevier Science. 2002,477 - 511.
26.Miyoshi Y, Yunoki M, Yano A, et al. Diencephalic syndrome of emaciation in an adult associated with a third ventricle intrinsic craniopharyngioma: case report. Neurosurgery, 2003, 227, 52(1): 224 -227.
27.El-Gamal, Nader MD, Frank, et al. Perioperative thermoregulatory dysfunction in a Patient with a Previous Traumatic Hypothalamic Injury.[Report].Anesthesia & Analgesia. 1995, 80(6): 1245-1247.
28.Lefranc F,Chevalier C,Vinchon M,et al.Characterization of the levels of expression of retinoic acid receptors,galectin-3,macrophage migration inhibiting factor,and P53 in 51adamantinomatous craniophryngioma.Journal of Neurosurgery.2003,98(1):145-153.
29.Yasargil MG,Curcic M,Kis M,et al.Total removal of craniopharyngiomas:Approaches and long-term results in 144 pations.J Neurosurgery,1990,73:3-11.
30.石样恩,王忠诚,张愬植等.颅咽管瘤全切术中的下丘脑功能保护.中华神经外科杂志,1999,15(6):342-344.
31.Bacldund E.Treatment of Craniopharyngiomas:The multi-modality approach.Presented at the Symposium on Craniopharyngioma:The Answer.New York,New York Medical Center,1993,12:17-19.
32.Erturk M,Kayalioglu G,Ozer MA.Morphometry of the anterior third ventricle region as a guide for the transcallosal-interforniceal approach.Neurol Med Chir,2004,44(6):288-292
33.Voges,Jurgen,Sturm,et al.Cystic Craniopharyngioma:Long-term Results after Intracavitary Irradiation with Stereotactically Applied Colloidal[beta]-Emitting Radioactive Sources.Neurosurgery.1997,40(2):263-270.
34.Pollock BE,Natt N,Schomberg PJ.Stereitactic management of craniopharyngioma Stereotactic & Functional Neurosurgery,2002,79(1):25-32.
35.Pereira P,Cerejo A,Cruz J,et al.Intracranial Aneurysm and Vasculopathy after Surgery and radiation therapy for Craniopharyngioma:Case Report.Neurosurgery.2002,50(4):885-888.
36.Chen C,Okera S,Davies PE,et al.Craniopharyngioma:a review of long-term visual outcome.Clin Experiment Ophthalmol.2003,31(3):220-228.
37.Takahashi H,Nakazawa S,Shirnura T.Evaluation of postoperative injection of bieomycin for craniopharyngioma in children.J Neurosurg,1985 62:120-127.
38.Broggi Q,Giorgi C,Franzini A,et al.Prelinunary results of intracavitary treatment of craniopharyngioma with bleomycin.J Neurosurg Sci,1989,33:145-148.
39.Kim SK,Wang KC,Shin SH,et al.Radical excision of pediatric craniopharyngioma:recurrence pattern and prognostic factors.Child's New Syst,2001,17(9):531-536.
40.Rajan B,Ashley S,Thomas DG,et al.Craniopharygioma:Improving outcome by early recognition and treatment of acute complications.Int J Radiat Oncol Biol Phys.1997,37:517- 521.
41.Pan J,Qi ST,Deng YJ,et al.Expression of proliferating cell nuclear antigen in craniopharyngioma and turnout recurrence.Di Yi JunYi DaXue XueBao.2002,22(4):363-365.
42.Nelson GA,Bastian FO,Schlitt M,et al.Malignant transformation in craniopharyngioma.Neurosurgery.1988,22(2):427-429.
43.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
44.Yasargil MG craniopharyngiomas.IN:Microneurosurgery of CNS Tumors,ed.Yasargil MG,Thieme,Medical Publishers,Inc,New York,1996,214.
45.Coutant R,Maurey H,Rouleau S,et al.Defect in epinephrine production in children with craniopharyngioma:functional or organic origin? J Clin Endocrinol Metab,2003,88(12):5969-5975.
46.Rojas EL,Al-Dweri FM,Lallena AM,et al.Dosimetry for radiocolloid therapy of cystic craniopharyngiomas.Med Phys,2003,30(9):2482-2492.
47.Caldarelli M,Di Rocco E,Papaci F,et al.Management of recurrent craniopharyngioma.Acta Neurochir(Wien),1998,140(5):447-454.
48.Wang KC,Kim SK,Choe G,et al.Growth patterns of craniopharyngioma in children:role of the diaphragm sellae and its surgical implication.Surg Neurol,2002,57(1):25-33.
49.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21(6):747-757.
50.漆松涛,潘军,黄胜平等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神经精神疾病杂志,2002,28(4):268-272.
51.漆松涛,潘军,陈状.儿童巨大颅咽管瘤12例手术治疗.中国神经精神疾病杂志,2004,30(6):475-476.
52.Taphoorn MJ,van Es C,Gooskens RH,et al.Children with craniopharyngioma,a "benign"brain tumor with a high morbidity.Ned Tijdschr Geneeskd,2000,144(36):1705-1709.
53.Kahn EA,Gosch HH,Seeger JF,et al.Forty-five years experience with the cran -iopharyngiomas.Surg Neurol,1973,1(1):5-12.
54.Adamson TE, Wiestler OD, Kleihues P, et al. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg, 1990, 73: 12 - 17.
55.Weiner HL, Wisoff JH, Rosenberg ME, et al.Craniopharyngiomas:A clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery, 1994, 35(6): 1001-1011.
56.Crotty TB, Scheithauer BW, Young WF, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg, 1995, 83(2): 206 - 214.
57.Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Nurosurg, 1999,90: 237 - 250.
58.Eldevik OP, Blaivas M, Gabrielsen TO, et al. Craniopharyngioma: radiologic and histologic findings and recurrence. AJNR Am J Neuroradiol, 1996, 17(8): 1427 - 1439.
59.Yoshihiko K, Kazuhiko M, Kazuhiko K, et al. MCM3-binding GANP DNA-primase is associated with a novel phosphatase compoment G5PR. Genes to cells. 2002, 7(8): 821 - 834.
2.Till K.Craniopharyngiomas.Childs Brain,1982,9:179.
3.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
4.Yasargil MG craniopharyngiomas.IN:Microneurosurgery of CNS Tumors,ed.Yasargil MG,Thieme,Medical Publishers,Inc,New York,1996,214.
5.Coutant R,Maurey H,Rouleau S,et al.Defect in epinephrine production in children with craniopharyngioma:functional or organic origin? J Clin Endocrinol Metab,2003,88(12):5969-5975.
6.Rojas EL,Al-Dweri FM,Lallena AM,et al.Dosimetry for radiocolloid therapy of cystic craniopharyngiomas.Med Phys,2003,30(9):2482-2492.
7.Caldarelli M,Di Rocco E,Papaci F,et al.Management of recurrent craniopharyngioma.Acta Neurochir(Wien),1998,140(5):447-454.
8.Wang KC,Kim SK,Choe G,et al.Growth patterns of craniopharyngioma in children:role of the diaphragm sellae and its surgical implication.Surg Neurol,2002,57(1):25-33.
9.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21(6):747-757.
10.漆松涛,潘军,黄胜平等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神经精神疾病杂志,2002,28(4):268-272.
11.漆松涛,潘军,陈状.儿童巨大颅咽管瘤12例手术治疗.中国神经精神疾病杂志,2004,30(6):475-476.
12.Im SH,Wang KC,Kim SK,et al.Transsphenoidal microsurgery for pediatric craniopharyngioma:special considerations regarding indications and method.Pediatr Neurosurg,2003,39(2):97-103.
13.Reyes F.Craniopharyngioma Recurrence.An R Acad Nac Med(Madr),2001,118(2):263-273.
14.Adamson TE,Wiestler OD,Kleihues P,et al.Correlation of clinical and pathological features in surgically treated craniopharyngiomas.J Neurosurg,1990,73:12-17.
15.Weiner HL,Wisoff JH,Rosenberg ME,et al.Craniopharyngiomas:A clinicopathological analysis of factors predictive of recurrence and functional outcome.Neurosurgery,1994,35(6):1001-1011.
16.Crotty TB,Scheithauer BW,Young WF,et al.Papillary craniopharyngioma:a clinicopathological study of 48 cases.J Neurosurg,1995,83(2):206-214.
17.Fahlbusch R,Honegger J,Paulus W,et al.Surgical treatment of craniopharyngiomas:experience with 168 patients.J Nurosurg,1999,90:237-250.
18.Eldevik OP,Blaivas M,Gabrielsen TO,et al.Craniopharyngioma:radiologic and histologic findings and recurrence.AJNR Am J Neuroradiol,1996,17(8):1427-1439.
19.Sweet WH.Craniopharyngiomas:asummaryofdata.In:Schmidek HH,ed.Operative neurosurgical techniques.4thed.London:ElsevierScience,2002:477-486.
20.潘军,漆松涛,邓永健,等.颅咽管瘤增殖细胞核抗原表达与肿瘤复发的关系.第一军医大学学报,2002,22(4):363-365.
21.Nishi T,Kurastu J,Takeshima H,et al.Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma.Int J Mol Med,1999,3(2):157-161.
22.Raghavan R,William T,Dickey,J,et al.Proliferative activity in craniopharyngiomas:clinicopathological correlations in adults and children.Surg Neurol,2000,54(3):241-248.
23.Beck GR Jr, Zerler B, Moran E.Phosphate is a specific signal for inductionof osteopontin gene expression. Proc Natl Acad Sci U S A, 2000, 97(15): 8352 - 8357.
24.Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J, 1993, 7(15):1475 -1482.
25.Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl. 1998, 30: 92 - 102.
26.Agrawal D, chen T, Irby R, etal. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst, 2003, 326 (10 - 11): 1041-1043.
27.Giancotti FG, Ruoslahti E. Integrin signaling. Science, 1999,285(5430): 1028 - 1032.
1.Agrawal D,chen T,Irby R,etal.Osteopontin identified as lead marker of colon cancer progression,using pooled sample expression profiling.J Natl Cancer Inst,2003;326(10-11):1041-1043.
2.Ishida K,Zhu BL,Maeda H.Novel approach to quantitative reverse transcription PCR assay of Mma component in autopsy material using the TaqMan fluorogenic detection system:dynamics of pulmonary surfactant apoprotein A.Forensic Sci Int.2000,113(1-3):127-131.
3.Higuchi R,Fockler C,et al.Kinetic PCR analysis:real-time monitoring of DNA amplification reactions.Biotechnology.1993,11(9):1026-1030.
4.Willard MR,Stephen JW,Kent EV Quantitative PT-PCR:pitfalls and potential.Biotechniques.1999,26,112-125.
5.Gabriel L,Armando P,Aidier S,et al.Craniopharyngioma in children:Marseille experience.Childs New Syst,2005,21(5):778-784.
6.Im SH,Wang KC,Kim SK,et al.Transsphenoidal microsurgery for pediatric craniopharyngioma:special considerations regarding indications and method.Pediatr Neurosurg,2003,39(2):97-103.
7.Kahn EA,Gosch HH,Seeger JF,et al.Forty-five years experience with the craniopharyngiomas.Surg Neurol,1973;1(3):5-12.
8.Weiner HL,Wisoff JH,Rosenberg ME,et al.Craniopharyngiomas:A clinicopathological analysis of factors predictive of recurrence and functional outcome.Neurosurgery,1994,35(6):1001-1011.
9.Adamson TE,Wiestler OD,Kleihues P,et al.Correlation of clinical and pathological features in surgically treated craniopharyngiomas.J Neurosurg,1990,73(1):12-17.
10.Fahlbusch R,Honegger J,Paulus W,et al.Surgical treatment of craniopharyngioma:experience with 168 patients.J Neurosurg,1999,90(2):237-250.
11.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21:747-757.
12.李士其.颅咽管瘤.见:徐启武,蒋雨平主编.第1版.临床颅脑病学.天津:天津科学技 术出版社,2003:278-283.
13.Kim SK,Wang KC,Shin SH,et al.Radical excision of pedi-atric craniopharyngioma:recurrence pattern and prognosticfac-tors.Child's Nerv Syst,2001,17(9):531-537.
14.Reizo Shirane,Ching-chanSu,YasukoKusaka,et al.Surgical outcomes in 31 patients with craniopharygiomas extending out-side the suprasellarcistern:ane valuation of the front obasalin-terhemispheric approach.J Neurosurg,2002,96(1):704-708.
15.潘军,漆松涛,邓永键等.颅咽管瘤增殖细胞核抗原表达与肿瘤复发的关系.第一军医大学学报,2002,22(4):363-366.
16.Sweet WH.Craniopharyngiomas:asummaryofdata.In:Schmidek HH,ed.Operative neurosurgical techniques.4thed.London:Elsevier Science,2002:477-486.
17.Senger DR,Wirth DF,Hynes R0.Transformed mammalian cells secrete specific proteins and phosphoproteins.Cell.1979,16(4):885-893.
18.Senger DR,Wirth DF,Hynes R0.Transformation-specific secreted phosphoproteins.Nature.1980,286(5773):619-621.
19.Oldberg A,Franzen A,Heinegard D.Cloning and sequence analysis of rat bone sialoprotein(osteopontin)cDNA reveals an Arg-Gly-Asp cell binding sequence.proc Natl Acad Sci USA.1986,83(23):8819-8823.
20.Coppola D,Correlation of osteopontin protein expression and pathological stage across a wide variety oftumorhistologies.Clin Cancer Res.2004,10(1):184-190.
21.Tuck AB,Chambers AF.The role of osteopontin in breast cancer:clinical and experimental studies.J Mammary Gland Biol Neoplasia,2001;6(4):419-429.
22.Ue T,Yokozaki H,Kitadai Y,et al.Co-expression of osteopontin and CD44v9 in gastriccancer.Int J Cancer.1998,79(2):127-132.
23.Casson AG,Wilson SM,McCart JA,etal.Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer.Int J Cancer,1997,72(5):739-745.
24.Thalmann GN,Sike RA,Devoll RE,et al.Osteopontin:possible role in prostate cancer progress.Clinical Cancer Res,1999,5(8):2271-2277.
25.Otte SJ,Winquist EW,Sititt L,et al.Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.Cancer.2002,95(3): 506-512.
26 Furger KA,Menon RK,Tuckl AB,et al.The functional and clinical roles of osteopontin in cancer and metastasis.Curr M1 Med.2001,1(5):621-632.
27.Tuck AB,O'Mallet FP,Singhal H,et al.Osteopontin and p53 expression are associated with tumor progression in a case of synchronous,bilateral,invasive mammary carcinomas.Arch Pathol Lab Med.1997,121(6):578-584.
28.Ye QH,Qin LX,Forgues M,et al.Predicting bepatitis B vinus-positive metastatic hepatocellular carcinomas using gene expression prof-fling and supervised machine learning.Nature Med.2003,9(4):416-423.
29.Shi jubo N,Uded T,Koo S,et al.Vascular endothelial growth facto and osteopontin in tumor biology.Crit Rev Oncog.2000,11(2):135-146.
30.Tuck AB,Chambers AF.The role of osteopontin in breast cancer:clinical and experimental studies.J Mamnar Y Gland Biol Neoplasia.2001,6(4):419-429.
31.Weinberger KM,Wiedenmann E,Bohm S,et al.Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system(Taq Man PCR).J Virol Methods.2000,85(1-2):75-82.
32.Eun AJ,Soeh M,Wong S,et al.Simultaneous quantitation of two orchid viruses by the Taq Man real-time RT-PCR.J Virol Methods.2000,87(1-2):151-160.
33.蒋春燕,王泰健,王琴.实时荧光定量PCR技术.动物医学进展.2005,12(1):101-105.
34.Kong DM,Huang YP,Zhang XB,et al.Duplex probes:a new approach for the detection of specific nucleic acids in homogenous assays.Analytic Chimica Acta,2003,491(3):135-143
35.张望.荧光实时定量PCR技术初探.生命科学趋势,2003,1(4):13-41.
36.Klein D.Quantification using real-time PCR technology:Applications and limitations.Trends Mol Med,2004,8(6):257-266
37.Sanford RA,Muhlbauer MS.Craniopharyngioma in children.Neurologic clinics,1991,9:453-465.
38.Lefranc F,Chevalier C,Vinchon M,et al.Characterization of the levels of expression of retinoic acid receptors,galectin-3,macrophage migration inhibiting factor,and p53 in 51adamantinomatous craniopharyngiomas.J eurosurg,2003,98(1):145-153.
39.漆松涛,潘军,黄胜平,等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神 经精神疾病杂志,2002,28(4):268-272.
40.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
1.Anderson RC,Grant JJ,de la Paz R,et al.Volumetric measurements in the detection of reduced ventricular volume in patients with normal pressure hydrocephalus whose clinical condition improved after ventriculoperitoneal shunt placement.J Neurosurg.2002,97(1),73-79.
2.Clatterbuck RE,Sipos EP.The efficient calculation of neurosurgically relevant volumes from computed tomographic scans using Cavalieri's Direct Estimator.Neurosurgery.1997,40(2):339-343.
3.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
4.Yasargil MG craniopharyngiomas.IN:Microneurosurgery of CNS Tumors,ed.Yasargil MG,Thieme,Medical Publishers,Inc,New York,1996,214.
5.Coutant R,Maurey H,Rouleau S,et al.Defect in epinephrine production in children with craniopharyngioma:functional or organic origin? J Clin Endocrinol Metab,2003,88(12):5969-5975.
6.Rojas EL,Al-Dweri FM,Lallena AM,et al.Dosimetry for radiocolloid therapy of cystic craniopharyngiomas.Med Phys,2003,30(9):2482-2492.
7.Caldarelli M,Di Rocco E,Papaci F,et al.Management of recurrent craniopharyngioma.Acta Neurochir(Wien),1998,140(5):447-454.
8.Wang KC,Kim SK,Choe G,et al.Growth patterns of craniopharyngioma in children:role of the diaphragm sellae and its surgical implication.Surg Neurol,2002,57(1):25-33.
9.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21(6):747-757.
10.漆松涛,潘军,黄胜平等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神经精神疾病杂志,2002,28(4):268-272.
11.漆松涛,潘军,陈状.儿童巨大颅咽管瘤12例手术治疗.中国神经精神疾病杂志,2004,30(6):475-476.
12.Ito M,Jamshidi J,Yamanaka K.Dose craniopharyngioma metastasize? case report and review of the literature.Neurosrugery,2001,48(4):933-935.
13.Novegno F,Di Rocco F,Colosimo Jr C,et al.Ectopic recurrences of craniopharyngioma.Childs New Syst,2002,18(9-10):468-473.
14.Kristopaitis T,Thomas C,Petruzzelli GJ,et al.Malignant craniopharyngioma.Arch Pathol Lab Med,2000;124(9):1356-1360.
15.Medico E,Gentile A,Lo Celso C,et al.Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth.Cancer Res.2001,61(15):5861-5868.
16.Shi jubo N,Uede T,Kon S,et al.Vascular endothelial growth factor and osteopontin in tumor biology.Crit Rev Oncog.2000,11(2):135-146.
17.Denhardt DT,Chamber AF.Overcoming obstacles to metastasis defenses against host defences:osteopontin(OPN)as a shield against attack by cytotoxic host cells.J Cellular Biochem.1994,56(1):48-51.
18.Vacca A,Ria R,Presta M,et al.Integrin alpha V beta 3 engagement modulates cell adehension,proliferation,and protease secretion in human lymphoid tumor cells.Exp Hematol.2001,29(8):993-1003.
19.Hotte S,Winquist EW,Stitt L,et al.Plasma osteopontin associations with survival and metastasis to bone in men with hormone refractory prostate carcinoma.Cancer.2002,95(3):516-512.
20.董俊峰,张占堆.51例颅内血肿量的新法计算探讨.河南实用神经疾病杂志.2002,(2):73-75.
21.Fucci MJ,Buchman CA,Brackmann DE,et al.Acoustic tumor growth:implica tions for treatment choices.Am J Otol.1999,20(4):495-499.
22.Tang Xi,HU Guoqing,Qiu Hong,et al.Comparing gross tumor volume of delineation between CT and MR/for nasopharygeal carcinoma.The Chinese-German Journal of Clinical Oncology.2005,4(3):141-145.
23.Hofmann UB,Westphal JR,Wass ET,et al.Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2(MMP-2)coincides with MMP-2 activation:correlation with melanoma progression.J Invest Dermatol.2000,115(4):625-632.
24.Silletti S,Kesster T,Goldberg J,et al.Disruption of matrix metalloproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo.Proc Natl Acta Sci USA.2001,98(1):119-124.
1.Giancotti FG, Ruoslahti E. Integrin signaling. Science, 1999, 285(5430): 1028 - 1032.
2.Gerber DJ, Pereira P, Huang SY, et allymphocytes. Expression of alpha v and beta 3 integrinchains on Proc Natl Acad Sci USA, 1996, 93(25): 14698 - 14703.
3.Smith LL, Cheung HK, Ling LE, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem, 1996, 271(45): 28485 -28491.
4.Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta, 2001,1552(2): 61-85.
5.Lesse BA. Adhesion molecules and implantation. J Reprod Immunol. 2002,55(1-2): 101-112.
6.Liaw L, Almeida M, Hart C E, et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res, 1994, 74(2): 214 - 224.
7. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol, 1996, 5(2): 127 - 135.
8.Furger KA, Allan AL, Wilson SM,et al. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res, 2003, 1(11): 810-819.
9.Senger DR, Ledbetter SR, Claffey KP, et al.Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol, 1996,149(1): 293-305.
10.Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol, 2000,156(5): 1673 - 1683.
11.Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling,and cell survival. J Clin. Invest, 2001,107(9): 1055-1061.
12.Engleman VW, Nickols GA, Ross FP,et al. A peptidomimetic antagonist of the alpha v beta 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest, 1997, 99(9): 2284-2292.
13.Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 2000,287(5454): 860 - 864.
14. Rabinowich H, Lin WC, Amoscato A,et al.Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. J Immunol,1995,154(3):1124-1135.
15.Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001,1552 (2): 61 - 85.
16.Hofmann UB, Westphal JR, Wass ET, et al. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2(MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol. 2000,115 (4): 625 - 632.
l7.Silletti S, Kesster T, Goldberg J, et al. Disruption of matrix metalloproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo. Proc Natl Acta Sci USA. 2001,98(1): 119- 124.
18.Furger KA, Alian AL, Wilson SM, et al. β_3 integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res. 2003, 1(11): 810-819.
19.Liapis H, Flath A, Kitazawa S, etal. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996,5 (2): 127 - 135.
20.Hofmann UB, Westphal JR, Wass ET, et al. Coexpression of integrin alpha V beta 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol. 2000,115 (4): 625 - 632.
21.Silletti S, Kesster T, Goldberg J, et al. Disruption of matrix metall oproteinase 2 binding to integrin alpha V beta 3 by an organic molecule inhibites angiogenesis and tumor growth in vivo. Proc Natl Acta Sci USA.2001, 98(1): 119 - 124.
22.Liu W, Matsumoto Y, Okada M, et al. Matrix metaploproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Medical Investigation. 2005, 52 (3-4): 151-158.
23.Paez PM, Ledda MF, Goldberg V, et al. High level of matrix metal oproteinases regulate proliferation and hormone secretion in pituitary cells. J Clinical Endocrinology Metasbolism. 2000, 85(1):263- 269.
24.Khabit AM, Nip J, Fallavollita L, et al. Regulation of urokinase plasminogen activator/plasmin- mediated invasion of melanoma cells by the integrin vitronectin receptor alpha V bete 3. Int Cance. 2001, 91(3): 300 - 308.
25.Mousa SA, Mohamed S, Wexler EJ, et al. Antiangiogenesis anticancer efficacy of TA138, a novel alpha V beta 3 antagonist. Anticancer Research. 2005,5 (1A): 197 - 206.
1.Beck GR Jr,Zerler B,Moran E.Phosphate is a specific signal for inductionof osteopontin gene expression.Proc Natl Acad Sci U S A,2000,97(15):8352-8357.
2.Ashkar S,Weber G.F,Panoutsakopoulou V,et al.Eta-1(osteopontin):an early component of type-1(cell-mediated)immunity.Science,2000,287(5454):860-864.
3.Fisher LW,McBride OW,Termine JD,Young MF.Human bone sialoprotein:Deduced protein sequence and chromosomal localization.J Biol Chem,1990,265(4):2347-2351.
4.Kohri K,Nomura S,Kitamura Y,et al.Structure and expression of the mRNA encoding urinary stone protein(osteopontin).J Biol Chem,1993,268(20):15180-15184.
5.Kohri K,Suzuki Y.,Yoshida K,et al.Molecular cloning and sequencing of cDNA encoding urinary stone protein,which is identical to osteopontin.Biochem Biophys Res Commun,1992,184(2):859-864.
6.Denhardt DT,Guo X.Osteopontin:a protein with diverse functions.FASEB J,1993,7(15):1475-1482.
7.Denhardt DT,Noda M.Osteopontin expression and function:role in bone remodeling.J Cell Biochem Suppl.1998,30:92-102.
8.Liaw L,Skinner MP,Raines EW,et al.The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins.Role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995,95(2): 713 - 724.
9. Xuan JW, Hota C, Shigeyama Y, et al. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem, 1995,57:680-690.
10.Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/ osteopontin gene. Crit Rev Immunol, 1993,13:225-246.
11.Scatena M, Almeida M, Chaisson ML, et al. NF-kappaB mediates avp3 integrin-induced endothelial cell survival. J Cell Biol, 1998,141(4): 1083 - 1093.
12.Hwang SM, Lopez CA, Heck DE, et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem. 1994, 269(1): 711-715.
13.Young MF, Kerr JM, Termine JD, et al. cDNA cloning. mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin(OPN). Genomics, 1990, 7: 49- 50.
14.Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.Anticancer Res. 1989, 9: 1291-1299.
15.Humphries MJ, Olden K, Yamada KM. A synthetic peptide from bronectininhibits experimental metastasis of murine melanoma cells. Science. 1986,233:467 - 470.
16.Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E. Role of the αvβ3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A. 1992, 89: 1557-1561.
17.Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and broblastic cells. Nature. 1983, 302: 714 -715.
18.Craig AM, Bowden GT, Chambers AF, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine broblasts. Int J Cancer. 1990,46: 133 - 137.
19.Ye QH, Qin LX, Forgoes M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 2003, 9(4): 416-423.
20.Behrend EI, Craig AM, Wioson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin 57 RNA. Cancer Res. 1994, 54:832 - 837.
21.Gardner HAR, Berse B, Senger DR. Speci.c reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat 1 .broblasts. Oncogene. 1994, 9: 2321 -2326.
22.Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression anddistribution in human carcinomas. Am J Pathol. 1994,145: 610 - 623.
23.Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim 3H, Cramer DW, Berkowitz RS,Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res, 2004,10(10): 3474 - 3478.
24.Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF,Yeatman TJ Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004,10(1 Pt I):184 - 190.
25.Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B,Cheifetz S. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis, 2000,18(3): 253 - 260.
26.Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe 从 Takahashi K, Fukuchi Y, Saijo N,Nishio K. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer, 2002,98(5) 707 -712.
27.Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES,Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem, 2002, 85(4): 728 - 736.
28.Crosby AH, Edwards SJ, Murray JC, Dixon MJ. Genomic organization of the human osteopontin gene: exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfecta type II. Genomics, 1995,27(1): 155 - 160.
29.Kiefer MC, Bauer DM, Barr PJ. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res, 1989,17(8): 3306 - 3312.
30.Shiraga H, Min W, VanDusen WJ, dayman MD, Miner D, Terrell CH, Sherbotie JR,Foreman JW, Prrysiecki C, Neilson EG,. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.Proc Natl Acad Sci U S A, 1992, 89(1): 426-430.
31.Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T lymphocyte activation-1/osteopontin gene. Crit Rev Immunol, 1993,13(3-4): 225 - 246.
32.Yamamoto S, Hijiya N, Setoguchi M, et al. Structure of the osteopontin gene and its promoter. Ann N Y Acad Sci, 1995, 760: 44 - 58.
33.O'Regan A,Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol, 2000,81(6): 373 - 390.
34.Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J, 1985,232(3): 715 - 724.
35.Oldberg A, Franzen A,Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A, 1986, 83(23): 8819 -8823.
36.Saitoh Y,Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest, 1995,72(1): 55 - 63.
37.Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta, 2001,1552(2): 61 - 85.
38.Bautista DS, Denstedt J, Chambers AF,Harris JF. Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem, 1996, 61(3): 402 - 409.
39.Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin - cleavage fragment of osteopontin. Biochim Biophys Acta, 1996,1314(1-2): 13-24.
40.Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res, 1985,45: 5818 - 5823.
41.Senger DR, Perruzzi CA, Papadopoulos-Sergiou A,Van de WL. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell, 1994, 5(5): 565 - 574.
42.Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ,Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 2000, 287(5454): 860 - 864.
43.Helluin O, Chan C, Vilaire q Mousa S, DeGrado WF,Bennett JS. The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J Biol Chem, 2000,275(24): 18337 - 18343.
44.Denhardt DT, Noda M, O'Regan AW, Pavlin D,Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest, 2001,107(9): 1055 - 1061.
45.Smith LL,Giachelli CM. Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res, 1998,242(1): 351 - 360.
46.Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R,Giachelli CM. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9betal integrin. J Biol Chem, 1996,271(45): 28485 - 28491.
47.Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SWYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem, 1999,274(51): 36328 - 36334.
48.Rangaswami H, Bulbule A, Kundu GC.Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol, 2006,16(2): 79 - 87.
49.Rittling SR, Chambers AF, et al. Role of osteopontin in tumor progression. Br J Cancer, 2004, 90(10): 1877-1881.
50.Wai PY, Kuo PV The role of osteopontin in tumor metastasis.J Surg Res, 2004, 121(2): 228-241.
51.Chakraborty G, Jain S, Behera R, et al. The multifaceted role of osteopontin in cell signaling tumor progression and angiogenesis. Curr Mol Med, 2006, 6(8): 819 - 830.
52. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF,Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol, 1994,145(3): 610-623.
53.Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer, 1996,15(3): 311 - 323.
54.Maki M, Hirota S, Kaneko Y,Morohoshi T. Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. Pathol Int, 2000,50(7): 531 - 535.
55.Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF,Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004,10(1): 184 - 190.
56.Crawford HC, Matrisian LM,Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res, 1998, 58(22): 5206 -5215
57.Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem, 2000, 77(3): 487 - 498.
58.Bourassa B, Monaghan S,Rittling SR. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol, 2004,227(1): 1-11.
59.Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB,Mukherjee BB. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry, 1997,36(19): 5729 - 5738.
60.Sodek J., Ganss B, Mckee MD. Osteopontin. Crti. Rev Oral Biol Med, 2000,11(3):279-303. 61.Chambers AF, Macdonald IC, Schmidt EE, et al. Clinical targets for anti- metastasis therapy. Adv Cancer Res, 2000, 79:91-121.
62.Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov, 2003,2(9): 703 - 716.
63.Weber GF. The metastasis gene osteopontin: a candidate for cancer therapy. Biochim. Biophy Acta, 2001,1552(2): 61 - 85.
64.Marroquin CE, Downky L, Guo H, et al. Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 marine leukemia cells [J]. Immunol Lett, 2004,95(1): 109 - 112.
65 .Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6,v9) expressicn by osteopontin in breast cancer epithelial cells facilitates tumor cell migratioru: novel post-transcriptional, post-translational regulation. Clin Exp Metastas, 2005,22(8): 663 - 673.
66.Al-Sharni K, Sorensen ES, EK-Rylander B, et al. Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 s6 kinase-dependent pathway. J Cell Biochem, 2005,94(6): 1218 - 1233.
67.Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear ractor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem, 2003, 278(31): 28593-28596.
68.Daffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des, 2004,10(1): 39-49.
69.Miz Guy H, Wai PY, et al. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in marine mammary epithelial cancer cells. Carcinogenesis, 2006,27(6): 1134 - 1145.
70.Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK /I_κB_α kinase-dependent nuclear factor κB-mediated promatrix, metalloproteinase-9 activation. J Biol Chem, 2004, 279(37): 38921 - 38935.
71.Rangasvrami H, Bulbule A, Kundu GC. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem, 2005, 280(19): 19381 - 392.
72.Jain S, Chakraborty q Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alphal/c-Src/IkappaB kinase kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res, 2006, 66(13): 6638 - 6648.
73.Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for abgiogenesis. Science, 1994, 264(5158): 569 - 571.
74. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and rumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival [J]. Mol Biol Cell, 2004, 15(6): 2834 - 2841.
75.Takahashi F, Akutagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer, 2002, 98(5): 707 - 712.
76.Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia, 2001, 6(4): 419 - 429.
77.Carlinfante G,Vassiliou D,Svensson O,et al.Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.Clin Exp Metastasis,2003,20(5):437-444.
78.Fedarko NS,Jain A,Karadag A,et al.Elevated serum bone sialoprotein and osteopontin in colon,breast,prostate,and lung cancer.Clin Cancer Res,2001,7(12):4060-4066.
79.Forootan SS,Foster CS,Aachi VR,et al.Prognostic si加ficance of osteopontin expression in human prostate cancer.Int J Cancer,2006,118(9):2255-2261.
80.Irby RB,McCarthy SM,Yeatman TJ.Osteopontin regulates multiple functions contributing to human colon cancer development and progression.Clin Exp Metastasis,2004,21(6):515-523.
81.Zhou Y,Dai DL,Martinka M,et al.Osteopontin expression correlates with melanoma invasion.J haves Dermatol,2005,124(5):1044-1052.
82.Boldrini L,Donati V,Dell'Omodarme M,et al.Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer.Br J Cancer,2005,93(4):453-457.
83.Kao CL,Chio SH,Ho DM et al.Elevation of plasma and cerebrospinal fluid Pathol,2005,123(2):297-304.
84.Wong TS,Kwong YL,Yuen AP.Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma.Eur J Surg Oncol,2005,31(5):555-558.
85.丁凌,郑树.骨桥蛋白在大肠癌和大肠癌肝转移中的表达及其临床意义.中华外科杂志,2002,40(10):773-775.
86.Renault MA,Jalvy S,Belloc I,Pasquet S,Sena S,Olive M,Desgranges C,Gadeau AP.AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells.Circ Res,2003,93(7):674-681.
87.Kohri K,Nomura S,Kitamura Y,Nagata T,Yoshioka K,Iguchi M,Yamate T,Umekawa T,Suzuki Y,Sinohara H,.Structure and expression of the mRNA encoding urinary stone protein (osteopontin).J Biol Chem,1993,268(20):15180-15184.
88.Yoshitake H,Riffling SR,Denhardt DT,Noda M.Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.Proc Natl Acad Sci U S A,1999,96(14):8156-8160.
89.Singh K,Balligand JL,Fischer TA,Smith TW,Kelly RA.Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells.Role in regulation of inducible nitric oxide synthase. J Biol Chem, 1995, 270(47): 28471 - 28478.
90.Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fieck E,Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation, 1997,96(9): 3063-3071.
91.Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM,Hogan BL. Altered wound healing in mice lacking a functional osteopontin gene (sppl). J Clin Invest, 1998,101(7): 1468 - 1478.
1.Schut L.Management of a pediatric hypothalamic mass.Neurosurgery.1996,38(4):806-811.
2.Till K.Craniopharyngiomas.Childs Brain,1982,9:179.
3.Sweet WH.Craniopharyngiomas:a summary of data.In:Schmidek HH,ed.Operative neurosurgical echniques.4~(th)ed.Vol 1,Health Science Asia,Elsevier cience;2002:477-486.
4.周良辅,主编.现代神经外科学.第一版.上海:上海医科大学出版社.2001.547-555.
5.姚志彬,主编.临床神经解剖学.第1版.广州:广东世界图书出版社.2001,255-290.
6.Lipscombe,Lorraine MD,Asa,Sylvia L.et al.Management of Lesions of the Pituitary Stalk and Hypothalamus.Endocrinologist.2003,13(1):38-51.
7.Henry,Thomas R.MD.Therapeutic mechanisms of vagus nerve stimulation.Neurology,2002,59(6):513-514.
8.Goldberg GM,Eshbaugh DE.Squamous cell nests of the pituitary gland as related to the origin of craniopharyngiomas:a study of the presence in the newborn and infants up to age four.Arch pathol,1996(70),293.
9.Shigeki Sekine,Tatsuhiro Shibata,Akiko Kokubu,et al.Craniopharygiomas of Adamantinomatoud Type Harbor β-Catenin Gene Mutations.American Journal of pathology,2002,161:1997-2001.
10.Rienstein S,Adams EF,Pilzer D,et al.Comparative genomic hybridization analysis of craniophryngioma.Journal of Neurosurgery,2003,98(1):162-164.
11.Alex F,Lesley S,Morris A,et al.Clinical Cancer Research.1999,5:2121-2132.
12.Paulus W,Stockel C,Krauss J,et al.Odontogenic classification of craniopharyngiomas:a cliniccopathological study of 54 cases.Histopathology,1997,30(2):172-176.
13.Adamson TE,Wiestler OD,Kleihues P,et al.Correlation of clinical and pathological features in surgically treated cranopharyngiomas.J Neurosurg,1990,73:12-17.
14.Xin W,Rubin MA,Mckeever.Differential expression of cytokerating 8 and 20distinguishes craniopharygioma from rathke cleft cyst.Archives of Pathology & Laboratory Medicine.2002,126(10):1174-1178.
15.Kawamata T, Kubo O, kamikawa S, et al. Ectopic clival craniopharyngioma. Acta Neurochirurgica, 2002,144(11): 1221 - 1224.
16.Liu JM, Garonzik IM, CG, et al. Ectopic recurrence of craniopharygioma after an interhenvspheric transcallosal approacha: case report.Neurosurgery. 2002,50(3): 639 - 644.
17.Henry H, Schmidek, MD, FACS. Operative neurosurgical techniques fourth edition. Health science Asia, Elsevier Science, 2002,477 - 511.
18.Hekmatpanah, Javad, et al. Transcortical-transventricular approach for removal of large third ventricle tumors. J Neurooncol, 2000,46(3): 277 - 280.
19.Belsham, Denise D, Cai, et al. Generation of a phenotypic array of hypothalamic neuronal cell models to study complex neuroendocrine disorders. Endocrinology. 2004,145(1): 393 - 400.
20.Funahashi H, Takenoya F, Guan Jl, et al. Hypothalamic neuronal networks and feeding-related peptides involved in the regulation of feeding. Anatomical Science International.2003 Sep, 78(3): 123 - 138.
21.Jung, H; Probst, E Neumaier, et al. Association of Morphological Characteristics with Precocious Puberty and/or Gelastic Seizures in Hypothalamic Hamartoma. Journal of Clinical Endocrinology & Metabolism. 2003, 88(10): 4590 - 4595.
22.Cho YK, Li CS, Smith DV ,et al. Descending influences from the lateral hypothalamus and amygdala converge onto medullary taste neurons. Chem. Senses 2003,28(2): 155 - 171.
23.Yang YK, Harmon CM, et al. Recent developments in our understanding of melanocortin system in the regulation of food intake. Obes Rev, 2003,4(4): 239 - 248.
24.Jansen HT, Cutter, et al. Seasonal Plasticity within the onadotropin-Releasing (GnRH) System of the Ewe: Changes in Identified GnRH Inputs and Glial Association. [Miscellaneous Article] .Endocrinology. 2003 Aug, 144(8): 3663 - 3676.
25.Henry H. Schmidek, MD, FACS. Operative neurosurgical techniques. Fourth Edition, Health science Asia, Elsevier Science. 2002,477 - 511.
26.Miyoshi Y, Yunoki M, Yano A, et al. Diencephalic syndrome of emaciation in an adult associated with a third ventricle intrinsic craniopharyngioma: case report. Neurosurgery, 2003, 227, 52(1): 224 -227.
27.El-Gamal, Nader MD, Frank, et al. Perioperative thermoregulatory dysfunction in a Patient with a Previous Traumatic Hypothalamic Injury.[Report].Anesthesia & Analgesia. 1995, 80(6): 1245-1247.
28.Lefranc F,Chevalier C,Vinchon M,et al.Characterization of the levels of expression of retinoic acid receptors,galectin-3,macrophage migration inhibiting factor,and P53 in 51adamantinomatous craniophryngioma.Journal of Neurosurgery.2003,98(1):145-153.
29.Yasargil MG,Curcic M,Kis M,et al.Total removal of craniopharyngiomas:Approaches and long-term results in 144 pations.J Neurosurgery,1990,73:3-11.
30.石样恩,王忠诚,张愬植等.颅咽管瘤全切术中的下丘脑功能保护.中华神经外科杂志,1999,15(6):342-344.
31.Bacldund E.Treatment of Craniopharyngiomas:The multi-modality approach.Presented at the Symposium on Craniopharyngioma:The Answer.New York,New York Medical Center,1993,12:17-19.
32.Erturk M,Kayalioglu G,Ozer MA.Morphometry of the anterior third ventricle region as a guide for the transcallosal-interforniceal approach.Neurol Med Chir,2004,44(6):288-292
33.Voges,Jurgen,Sturm,et al.Cystic Craniopharyngioma:Long-term Results after Intracavitary Irradiation with Stereotactically Applied Colloidal[beta]-Emitting Radioactive Sources.Neurosurgery.1997,40(2):263-270.
34.Pollock BE,Natt N,Schomberg PJ.Stereitactic management of craniopharyngioma Stereotactic & Functional Neurosurgery,2002,79(1):25-32.
35.Pereira P,Cerejo A,Cruz J,et al.Intracranial Aneurysm and Vasculopathy after Surgery and radiation therapy for Craniopharyngioma:Case Report.Neurosurgery.2002,50(4):885-888.
36.Chen C,Okera S,Davies PE,et al.Craniopharyngioma:a review of long-term visual outcome.Clin Experiment Ophthalmol.2003,31(3):220-228.
37.Takahashi H,Nakazawa S,Shirnura T.Evaluation of postoperative injection of bieomycin for craniopharyngioma in children.J Neurosurg,1985 62:120-127.
38.Broggi Q,Giorgi C,Franzini A,et al.Prelinunary results of intracavitary treatment of craniopharyngioma with bleomycin.J Neurosurg Sci,1989,33:145-148.
39.Kim SK,Wang KC,Shin SH,et al.Radical excision of pediatric craniopharyngioma:recurrence pattern and prognostic factors.Child's New Syst,2001,17(9):531-536.
40.Rajan B,Ashley S,Thomas DG,et al.Craniopharygioma:Improving outcome by early recognition and treatment of acute complications.Int J Radiat Oncol Biol Phys.1997,37:517- 521.
41.Pan J,Qi ST,Deng YJ,et al.Expression of proliferating cell nuclear antigen in craniopharyngioma and turnout recurrence.Di Yi JunYi DaXue XueBao.2002,22(4):363-365.
42.Nelson GA,Bastian FO,Schlitt M,et al.Malignant transformation in craniopharyngioma.Neurosurgery.1988,22(2):427-429.
43.Yasargil MG,Crucic M,Kis M,et al.Total removal of craniopharyngiomas.J Neurosurgery,1990,73(1):3-11.
44.Yasargil MG craniopharyngiomas.IN:Microneurosurgery of CNS Tumors,ed.Yasargil MG,Thieme,Medical Publishers,Inc,New York,1996,214.
45.Coutant R,Maurey H,Rouleau S,et al.Defect in epinephrine production in children with craniopharyngioma:functional or organic origin? J Clin Endocrinol Metab,2003,88(12):5969-5975.
46.Rojas EL,Al-Dweri FM,Lallena AM,et al.Dosimetry for radiocolloid therapy of cystic craniopharyngiomas.Med Phys,2003,30(9):2482-2492.
47.Caldarelli M,Di Rocco E,Papaci F,et al.Management of recurrent craniopharyngioma.Acta Neurochir(Wien),1998,140(5):447-454.
48.Wang KC,Kim SK,Choe G,et al.Growth patterns of craniopharyngioma in children:role of the diaphragm sellae and its surgical implication.Surg Neurol,2002,57(1):25-33.
49.Caldarelli M,Massimi L,Tamburrini G,et al.Long-term results of the surgical treatment of craniopharyngioma:the experience at the Policlinico Gemelli,Catholic University,Rome.Child New Syst,2005,21(6):747-757.
50.漆松涛,潘军,黄胜平等.大型颅咽管瘤生长方向及侵袭特征与手术效果探讨.中国神经精神疾病杂志,2002,28(4):268-272.
51.漆松涛,潘军,陈状.儿童巨大颅咽管瘤12例手术治疗.中国神经精神疾病杂志,2004,30(6):475-476.
52.Taphoorn MJ,van Es C,Gooskens RH,et al.Children with craniopharyngioma,a "benign"brain tumor with a high morbidity.Ned Tijdschr Geneeskd,2000,144(36):1705-1709.
53.Kahn EA,Gosch HH,Seeger JF,et al.Forty-five years experience with the cran -iopharyngiomas.Surg Neurol,1973,1(1):5-12.
54.Adamson TE, Wiestler OD, Kleihues P, et al. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. J Neurosurg, 1990, 73: 12 - 17.
55.Weiner HL, Wisoff JH, Rosenberg ME, et al.Craniopharyngiomas:A clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery, 1994, 35(6): 1001-1011.
56.Crotty TB, Scheithauer BW, Young WF, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg, 1995, 83(2): 206 - 214.
57.Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Nurosurg, 1999,90: 237 - 250.
58.Eldevik OP, Blaivas M, Gabrielsen TO, et al. Craniopharyngioma: radiologic and histologic findings and recurrence. AJNR Am J Neuroradiol, 1996, 17(8): 1427 - 1439.
59.Yoshihiko K, Kazuhiko M, Kazuhiko K, et al. MCM3-binding GANP DNA-primase is associated with a novel phosphatase compoment G5PR. Genes to cells. 2002, 7(8): 821 - 834.